STERIS announced fiscal 2027 first quarter revenue increased 7% to $1.5 billion, with constant currency organic revenue growth of 6%. As reported diluted earnings per share rose to $2.04 from $1.79 a year earlier, while adjusted diluted EPS climbed to $2.59 from $2.34. The company also unveiled a targeted restructuring plan tied to a new Formulated Chemistries Center of Excellence in North Carolina, which will consolidate manufacturing and distribution and lead to the closure of facilities in St. Louis, Missouri, and Plymouth, Minnesota. STERIS expects to incur total pre-tax restructuring charges of approximately $55 million to $70 million, with completion anticipated during fiscal 2030. The company reiterated its full-year fiscal 2027 outlook for revenue growth of 7-8% and adjusted EPS of $11.10 to $11.30, while raising its capital expenditure forecast to approximately $450 million and lowering its free cash flow expectation to approximately $800 million.
STERIS plcRevenue and EPS growth beat expectations, with raised capex and reiterated guidance.
